Maxim Group set a $12.00 price objective on Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Monday, January 8th. The brokerage currently has a buy rating on the medical research company’s stock.
A number of other research analysts also recently issued reports on CTSO. ValuEngine downgraded Cytosorbents from a hold rating to a sell rating in a research note on Monday, October 2nd. HC Wainwright restated a buy rating and issued a $13.00 price target on shares of Cytosorbents in a research note on Tuesday, September 26th. Finally, B. Riley restated a buy rating and issued a $11.25 price target on shares of Cytosorbents in a research note on Friday, November 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Cytosorbents has a consensus rating of Buy and a consensus target price of $10.60.
Cytosorbents (CTSO) remained flat at $$7.80 during trading on Monday. 133,400 shares of the stock traded hands, compared to its average volume of 133,008. The firm has a market capitalization of $223.79, a P/E ratio of -20.53 and a beta of -0.54. Cytosorbents has a 52-week low of $3.30 and a 52-week high of $7.90. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73.
In related news, CFO Kathleen P. Bloch sold 32,400 shares of the stock in a transaction on Monday, January 8th. The stock was sold at an average price of $7.30, for a total transaction of $236,520.00. Following the sale, the chief financial officer now owns 248,638 shares in the company, valued at approximately $1,815,057.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Vincent Capponi sold 4,000 shares of the stock in a transaction on Monday, November 27th. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the chief operating officer now owns 271,062 shares in the company, valued at approximately $1,897,434. The disclosure for this sale can be found here. 5.60% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Fortaleza Asset Management Inc. raised its holdings in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after buying an additional 10,500 shares during the period. PNC Financial Services Group Inc. raised its holdings in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in Cytosorbents in the third quarter worth $365,000. Finally, Skylands Capital LLC increased its stake in Cytosorbents by 45.1% in the fourth quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock worth $4,716,000 after purchasing an additional 225,558 shares during the period. Institutional investors own 8.65% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/cytosorbents-ctso-given-a-12-00-price-target-by-maxim-group-analysts/1821680.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.